Antibody levels may predict COVID-19 reinfection risk

NCT ID NCT05365750

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study followed 4,235 Kaiser Permanente Colorado members to track COVID-19 antibodies and reinfection rates over 9 months. Researchers measured antibody levels and tested for new infections to see if antibody levels could predict reinfection risk. The goal was to better understand how long immunity lasts after a first infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help predict who is at risk for reinfection based on antibody levels.

What could go wrong

This is an observational study, not a treatment trial. Results may not apply to other populations or variants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kaiser Permanente

    Aurora, Colorado, 80014, United States